SYNTi

SYNTi is a PDZ domain inhibitor targeting the syndecan/syntenin protein-protein Interaction. SYNTi exhibits an IC50 value of 400 nM and ligand efficiency (LE) value of 0.24. SYNTi can be used for breast cancer research[1].

Product Specifications

UNSPSC

12352005

Target

SDCBP

Type

Reference compound

Related Pathways

Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/synti.html

Solubility

10 mM in DMSO

Smiles

O=C1N(CC2=CC(Br)=CC=C21)[C@H](C(N[C@H](C(O)=O)C)=O)CC3=CC=C(C=C3)C4=CC(C(C)=O)=CC=C4F

Molecular Formula

C28H24BrFN2O5

Molecular Weight

567.40

References & Citations

[1]Hoffer L, et al. Discovery of a PDZ Domain Inhibitor Targeting the Syndecan/Syntenin Protein-Protein Interaction: A Semi-Automated "Hit Identification-to-Optimization" Approach. J Med Chem. 2023 Apr 13;66 (7) :4633-4658.